Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03389230 · ClinicalTrials.gov registry record · Phase 1
Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma
A Phase 1 study of Glioblastoma and Malignant Glioma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT03389230 is a Phase 1 study of Glioblastoma and Malignant Glioma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 29 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03389230, a Phase 1 study of Glioblastoma and Malignant Glioma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment (refractory). Memory enriched T cells such as HER2(EQ)BBζ/CD19t+ T cells may enter and express its genes in immune cells. Immune cells can be engineered to kill glioma cells in the laboratory by inserting a piece of deoxyribonucleic acid (DNA) into the immune cells that allows them to recognize glioma cells. A vector called lentivirus is used to carry the piece of DNA into the immune cell. It is not known whether these immune cells will kill glioma tumor cells when given to patients.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Leukapheresis
- BIOLOGICAL HER2(EQ)BBζ/CD19t+ T cells
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-08-14 |
| Est. Completion | 2026-12-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03389230
The ClinicalTrials.gov registry entry for NCT03389230 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (73% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03389230 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03389230 about?
NCT03389230 is a clinical study titled "Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma". This phase I trial studies the side effects and best dose of memory-enriched T cells in treating patients with grade II-IV glioma that has come back (recurrent) or does not respond to treatment (refractory). Memory enriched T cells such as HER2(EQ)BBζ/CD19t+ T cells may enter and express its genes i...
What is the current status of trial NCT03389230?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-08-14. Estimated completion is 2026-12-29.
What conditions does trial NCT03389230 study?
This clinical trial studies the following conditions: Glioblastoma, Malignant Glioma, Recurrent Glioma, WHO Grade III Glioma, Refractory Glioma.
What interventions are being tested in trial NCT03389230?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Leukapheresis (PROCEDURE), HER2(EQ)BBζ/CD19t+ T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT03389230?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03389230 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.